It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival

Michael C. Roach, Sana Rehman, Todd DeWees, Christopher D. Abraham, Jeffrey D. Bradley, Cliff G. Robinson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients to quit smoking in follow-up. We evaluated whether there was a survival benefit to smoking cessation after SBRT. Methods and materials: Patients with early-stage NSCLC treated from 2004 to 2013 who were still smoking tobacco at the time of SBRT were identified from a prospective institutional review board-approved registry. Peripheral tumors were treated to 54 Gy in 3 fractions and central tumors to 50 Gy in 5 fractions. Patients were reviewed for overall survival (OS) and disease progression. The log-rank and Cox regression tests were used to identify factors predictive of OS. Results: Thirty-two patients (27%) quit smoking after SBRT, and 87 (73%) continued smoking. Median follow-up was 22 months (range, 2-87). On multivariate analysis, smoking status (hazard ratio, 2.1; 95% confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score and larger tumor size were predictive of worse OS. The prior number of cigarette pack-years was not significant (. P = .62). In a Kaplan-Meier comparison, smoking cessation after SBRT was associated with improved 2-year OS, 78% versus 69% (. P = .014). There was no significant difference in 2-year progression-free survival (75% vs 55%, P = .23) or local control (97% vs 88%, P = .63). Conclusion: OS is significantly improved in patients who stop smoking after SBRT for early-stage NSCLC, no matter their previous smoking history. Encouraging smoking cessation should be an important part of every posttreatment visit.

Original languageEnglish (US)
Pages (from-to)12-18
Number of pages7
JournalPractical Radiation Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Smoking Cessation
Non-Small Cell Lung Carcinoma
Radiotherapy
Smoking
Survival
Pyridinolcarbamate
Neoplasms
Research Ethics Committees
Tobacco Products
Disease-Free Survival
Registries
Disease Progression
Comorbidity
Multivariate Analysis
History
Confidence Intervals

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

It's never too late : Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. / Roach, Michael C.; Rehman, Sana; DeWees, Todd; Abraham, Christopher D.; Bradley, Jeffrey D.; Robinson, Cliff G.

In: Practical Radiation Oncology, Vol. 6, No. 1, 01.01.2016, p. 12-18.

Research output: Contribution to journalArticle

Roach, Michael C. ; Rehman, Sana ; DeWees, Todd ; Abraham, Christopher D. ; Bradley, Jeffrey D. ; Robinson, Cliff G. / It's never too late : Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. In: Practical Radiation Oncology. 2016 ; Vol. 6, No. 1. pp. 12-18.
@article{62b9042ae0d14ede88607a2ee41a1ae4,
title = "It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival",
abstract = "Purpose: As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients to quit smoking in follow-up. We evaluated whether there was a survival benefit to smoking cessation after SBRT. Methods and materials: Patients with early-stage NSCLC treated from 2004 to 2013 who were still smoking tobacco at the time of SBRT were identified from a prospective institutional review board-approved registry. Peripheral tumors were treated to 54 Gy in 3 fractions and central tumors to 50 Gy in 5 fractions. Patients were reviewed for overall survival (OS) and disease progression. The log-rank and Cox regression tests were used to identify factors predictive of OS. Results: Thirty-two patients (27{\%}) quit smoking after SBRT, and 87 (73{\%}) continued smoking. Median follow-up was 22 months (range, 2-87). On multivariate analysis, smoking status (hazard ratio, 2.1; 95{\%} confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score and larger tumor size were predictive of worse OS. The prior number of cigarette pack-years was not significant (. P = .62). In a Kaplan-Meier comparison, smoking cessation after SBRT was associated with improved 2-year OS, 78{\%} versus 69{\%} (. P = .014). There was no significant difference in 2-year progression-free survival (75{\%} vs 55{\%}, P = .23) or local control (97{\%} vs 88{\%}, P = .63). Conclusion: OS is significantly improved in patients who stop smoking after SBRT for early-stage NSCLC, no matter their previous smoking history. Encouraging smoking cessation should be an important part of every posttreatment visit.",
author = "Roach, {Michael C.} and Sana Rehman and Todd DeWees and Abraham, {Christopher D.} and Bradley, {Jeffrey D.} and Robinson, {Cliff G.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.prro.2015.09.005",
language = "English (US)",
volume = "6",
pages = "12--18",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - It's never too late

T2 - Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival

AU - Roach, Michael C.

AU - Rehman, Sana

AU - DeWees, Todd

AU - Abraham, Christopher D.

AU - Bradley, Jeffrey D.

AU - Robinson, Cliff G.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients to quit smoking in follow-up. We evaluated whether there was a survival benefit to smoking cessation after SBRT. Methods and materials: Patients with early-stage NSCLC treated from 2004 to 2013 who were still smoking tobacco at the time of SBRT were identified from a prospective institutional review board-approved registry. Peripheral tumors were treated to 54 Gy in 3 fractions and central tumors to 50 Gy in 5 fractions. Patients were reviewed for overall survival (OS) and disease progression. The log-rank and Cox regression tests were used to identify factors predictive of OS. Results: Thirty-two patients (27%) quit smoking after SBRT, and 87 (73%) continued smoking. Median follow-up was 22 months (range, 2-87). On multivariate analysis, smoking status (hazard ratio, 2.1; 95% confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score and larger tumor size were predictive of worse OS. The prior number of cigarette pack-years was not significant (. P = .62). In a Kaplan-Meier comparison, smoking cessation after SBRT was associated with improved 2-year OS, 78% versus 69% (. P = .014). There was no significant difference in 2-year progression-free survival (75% vs 55%, P = .23) or local control (97% vs 88%, P = .63). Conclusion: OS is significantly improved in patients who stop smoking after SBRT for early-stage NSCLC, no matter their previous smoking history. Encouraging smoking cessation should be an important part of every posttreatment visit.

AB - Purpose: As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients to quit smoking in follow-up. We evaluated whether there was a survival benefit to smoking cessation after SBRT. Methods and materials: Patients with early-stage NSCLC treated from 2004 to 2013 who were still smoking tobacco at the time of SBRT were identified from a prospective institutional review board-approved registry. Peripheral tumors were treated to 54 Gy in 3 fractions and central tumors to 50 Gy in 5 fractions. Patients were reviewed for overall survival (OS) and disease progression. The log-rank and Cox regression tests were used to identify factors predictive of OS. Results: Thirty-two patients (27%) quit smoking after SBRT, and 87 (73%) continued smoking. Median follow-up was 22 months (range, 2-87). On multivariate analysis, smoking status (hazard ratio, 2.1; 95% confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score and larger tumor size were predictive of worse OS. The prior number of cigarette pack-years was not significant (. P = .62). In a Kaplan-Meier comparison, smoking cessation after SBRT was associated with improved 2-year OS, 78% versus 69% (. P = .014). There was no significant difference in 2-year progression-free survival (75% vs 55%, P = .23) or local control (97% vs 88%, P = .63). Conclusion: OS is significantly improved in patients who stop smoking after SBRT for early-stage NSCLC, no matter their previous smoking history. Encouraging smoking cessation should be an important part of every posttreatment visit.

UR - http://www.scopus.com/inward/record.url?scp=84952981121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952981121&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2015.09.005

DO - 10.1016/j.prro.2015.09.005

M3 - Article

C2 - 26598909

AN - SCOPUS:84952981121

VL - 6

SP - 12

EP - 18

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 1

ER -